L. Karlin - Hosp Civils Lyon, Ctr Hosp Lyon Sud

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 15 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

PO-05: D-dimers cut off level to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma

S. Charles, A. Chaudier, T. Fatrara, E. Daguenet,L. Karlin, A. Montmartin, K. Boussoualim, B. Tardy-Poncet, B. Tardy, T. Lecompte, D. Guyotat, E. Chalayer

THROMBOSIS RESEARCH（2022）

引用1浏览0引用

Subcutaneous Daratumumab (DARA SC) with Standard-ofCare (SoC) in Multiple Myeloma (MM) across therapy lines in phase 2 PLEIADES: Initial results with SoC Carfilzomib/Dexamethasone (D-Kd) and updated results with SoC Bortezomib/Melphalan/Prednisone (D-VMP) or Lenalidomide/Dexamethasone (D-Rd)

H. Goldschmidt,A. Chari, M. Haenel,A. Oriol,P. Rodriguez-Otero,H. McCarthy,K. Suzuki, V Hungria,A. Sureda Balari, L. Clement-Filliatre,C. Hulin,H. Magen,

ONCOLOGY RESEARCH AND TREATMENT（2021）

引用0浏览0引用

Pomalidomide in lenalidomide-refractory multiple myeloma: far from futile (vol 188, pg 483, 2020)

Mo, Richardson,J. San-Miguel,K. Weisel,P. Moreau,M. Lacy,K. Song, M. Delforge,L. Karlin, H. Goldschmidt,A. Banos,A. Oriol,

BRITISH JOURNAL OF HAEMATOLOGY（2020）

引用3浏览0引用

Continuous Lenalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and Renal Impairment in the First Trial

M. Dimopoulos,M. Cheung,M. Roussel, T. Liu,B. Gamberi,B. Kolb, H.G. Derigs,H. Eom,K. Belhadj,P. Lenain,R. van der Jagt,S. Rigaudeau,

Clinical Lymphoma, Myeloma & Leukemia（2015）

引用1浏览0引用

1567 Overview of French routine clinical practice for the management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa in 1298 patients with solid tumors: A national observational study (The OncoBOS study)

J.P. Metges, N. Khobta,G. Boschetti,L. Karlin,A. Toledano, C. Aubron-olivier,D. Fernet,Olivier Fitoussi

EUROPEAN JOURNAL OF CANCER（2015）

引用1浏览0引用

IMPACT OF RENAL IMPAIRMENT ON OUTCOMES AFTER TREATMENT WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FIRST TRIAL RESULTS

M. Dimopoulos,M. Cheung,M. Roussel, T. Liu,B. Gamberi,B. Kolb, H. G. Derigs,H. Eom,K. Belhadj,P. Lenain,R. van der Jagt,S. Rigaudeau,

HAEMATOLOGICA（2015）

引用0浏览0引用

THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR ONO-4059: PROMISING SINGLE AGENT ACTIVITY IN PATIENTS WITH RELAPSED AND REFRACTORY NHL

F. Morschhauser,L. Terriou,M. Dyer,C. Hutchinson,S. Rule,N. Shah,G. Salles,L. Karlin,C. Fegan, J. Bagshawe, G. Cartron,H. Honda,

HAEMATOLOGICA（2014）

引用0浏览0引用

A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma

N. K. Shah,S. Rule,G. Salles,L. Karlin,F. Morschhauser,L. Terriou,M. Dyer,C. Hutchinson,C. Fegan, A. Davison, G. Cartron,J. G. Wright,

BRITISH JOURNAL OF HAEMATOLOGY（2014）

引用28浏览0引用

ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

K. Weisel, M. Dimopoulos,P. Moreau,M. Lacy,K. Song, M. Delforge,L. Karlin, H. Goldschmidt,A. Banos,A. Oriol,A. Alegre,C. Chen,

HAEMATOLOGICA（2013）

引用0浏览0引用

EFFICACY, SAFETY, AND QOL IN MM-003, A PHASE3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) VS HIGH-DOSE DEXAMETHASONE (HIDEX) IN RRMM

J. Miguel,K. Weisel,P. Moreau,M. Lacy,K. Song, M. Delforge,L. Karlin, H. Goldschmidt,A. Banos,A. Oriol,A. Alegre,C. Chen,

HAEMATOLOGICA（2013）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn